The Bio/Pharma Beat

    View Author January 2020

    We would like to share with you the Bio/Pharma Beat, our monthly newsletter reporting on the patent law developments you should know in biotech, biologics and pharmaceutical cases, legislation and federal agency actions. This month’s issue covers relevant news from December 2019, including:

    • The Solicitor General, on behalf of the US, asserts that the Supreme Court’s Section 101 precedent creates “substantial uncertainty” requiring clarification
    • The Federal Circuit holds that there is no single entity requirement for infringement under section 271(g)
    • A district court holds that, under certain circumstances, an anticipatory reference is not necessarily “but-for” material under an inequitable conduct analysis